

## Biological Warfare Agent Laboratory Diagnosis and Biosafety Concerns

Lucky Gupta\*

Department of Medical Microbiology, India

### Abstract

Bioterrorism events have been rare until lately numerous clinical laboratories may not be familiar with handling samples from a possible bioterrorism attack. Thus, they should be apprehensive of their own liabilities and limitations in the running and treatment of similar samples, and what to do if they're requested to reuse clinical samples. The Centers for Disease Control and Prevention has developed the Laboratory Response Network to give a systematized response system for the discovery and opinion of natural warfare agents grounded on laboratory testing capacities and installations. There are potentially numerous natural warfare agents, but presumably a limited number of agents would be encountered in case of an attack, and their identification and laboratory safety will be banded.

**Keywords:** Biosafety bioterrorism; Biological warfare; Bacillus anthracis; Francisella tularensis; Clostridium botulinum

### Introduction

A great variety of natural agents could potentially be used for natural warfare, but fortunately only a many agents can be efficiently circulated in the community. As well as being fluently dispersed (1-5- $\mu$ m patches), the ' ideal ' natural agents should be largely murderous, fluently produced in large amounts, stable, rather transmitted by the aerosol route or from person to person, resistant to standard antibiotics, and not preventable by vaccination. This limits the list of possible agents to certain bacteria (Bacillus anthracis, Brucellaspp., Clostridium botulinum, Yersinia pestis, and Francisella tularensis) and contagions( smallpox and viral hemorrhagic complications),(2). Among these, Bacillus anthracis and smallpox are the two agents with the most implicit to fulfill the criteria for mass casualties. Until lately, bioterrorism was a veritably rare event, and the agents involved in it were hardly ever encountered in( clinical) laboratories; hence laboratory labor force aren't familiar with the appearance and characteristics of these agents, or with the event, handling and laboratory treatment of clinical samples. Owing to the present events, clinical laboratories may be requested to reuse clinical or environmental samples ( from real or humbug attacks) [1-3].

Thus, all microbiological laboratories should be familiar with the styles and palladium measures involved in handling these agents. The Centers for Disease Control and Prevention (CDC) has created the Laboratory Response Network to give a systematized response system for the discovery and opinion of natural warfare agents grounded on laboratory testing capacities and installations. There are four situations of laboratory capacity (A – D), and each position has designated core-testing capacities. Level A laboratories have the minimal core capacity, and they would rule out suspected isolates by simple testing and relate them to an advanced- position laboratory. Position D laboratories, like the CDC, are natural safety position 4(BSL- 4) installations, and they've the loftiest capacity and most advanced

Containment involves the use of safe styles for managing contagious accoutrements in the laboratory terrain. Its purpose is to reduce or exclude exposure of laboratory workers and the terrain to potentially dangerous agents( 5). Primary constraint is the protection of labor force and the immediate laboratory terrain; secondary constraint is the protection of the terrain external to the laboratory. Hence, the three most important motifs in laboratory safety are laboratory practice and ways safety outfit; and design of installations. Laboratory labor force must always be apprehensive of the implicit hazards when

working with clinical samples. As a result, strict adherence to standard microbiological practices and ways is the most important factor in constraint, and each laboratory should develop a biosafety primer. To minimize and/ or exclude exposure to certain agents, laboratory labor force must be continually trained to insure mindfulness of individual and preventative measures. Safety outfit comprises primary walls against natural accoutrements; including natural safety closets (BSCs), enclosed holders, and other engineering controls.

### Discussion

Safety outfit may also include particulars for particular protection, similar as gloves, face securities, and safety spectacles, which are frequently used in combination with a BSC. There are presently three types of BSC open- fronted class I and II BSCs offer protection to laboratory labor force and to the terrain; class II BSCs also give protection from external impurity; and the gas-tight class III BSC provides the loftiest attainable position of protection to labor force and terrain. The secondary walls will depend on the threat of transmission of specific agent. The design and the construction of the laboratory installation form part of these secondary walls. They should contribute to the laboratory workers' protection, as well as cover the community terrain from contagious agents which may be accidentally released from the laboratory. The viral hemorrhagic fever pattern may be caused by several RNA contagions from the Filoviridae, Arenaviridae, Bunyaviridae, and Flaviviridae. These contagions are largely contagious by the aerosol route [4-6].

Only BSL- 4 installations are equipped for the opinion of viral hemorrhagic complications. Culture, serology, Immunohistochemical ways and modification styles are used for opinion. Blood, urine and throat hearties or washings are used for contagion insulation; liver necropsies are used posthumous. Contagion insulation is generally successful only if samples are attained within the first many days of

**\*Corresponding author:** Lucky Gupta, Department of Medical Microbiology, India, E-mail: lucky.gp22@gmail.com

**Received:** 3-Jan-2023, Manuscript No: jbtbd-23-85663, **Editor assigned:** 06-Jan-2023, PreQC No: jbtbd-23-85663 (PQ), **Reviewed:** 20-Jan-2023, QC No: jbtbd-23-85663, **Revised:** 23-Jan-2023, Manuscript No: jbtbd-23-85663 (R) **Published:** 30-Jan-2023, DOI: 10.4172/2157-2526.1000316

**Citation:** Gupta L (2023) Biological Warfare Agent Laboratory Diagnosis and Biosafety Concerns. J Bioterr Biodef, 14: 316.

**Copyright:** © 2023 Gupta L. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

illness. For insulation, blood, cerebrospinal fluid, brain or other napkins should be collected, and cooled at 4 °C. Heparinized whole blood or homogenized clots are satisfactory for contagion isolation. *Brucella* species are small, noiselessly staining, Gram-negative, single- appearing coccobacilli or short rods, arranged in dyads and short chains. They're on-motile, non-sporulation strict aerobes, generally oxidase positive, catalase positive, and urease variable. The metabolism of *Brucella* is substantially oxidative on carbohydrates in conventional media.

Thiamine, niacin and biotin are needed for growth; some strains bear the addition of serum. The optimal growth temperature is 37 °C, with a range between 10 °C and 40 °C (16). The rubric *Brucella* has six species — *Brucella abortus*, *Brucella melitensis*, *Brucella Suis*, *Brucella canis*, *Brucella ovens*, and *Brucella neuroma* each including different biotypes. Of those species, the first four are associated with mortal complaint, *Brucella melitensis* being considered the most malign. Reports have been published of *Brucella* as an occupational hazard to laboratory workers. Since *Brucella* infects the reticuloendothelial system, blood and bone gist are pivotal clinical samples. Depending on the contagious complications, other samples (cerebrospinal fluid, necropsies, abscess, etc.) should be submitted for culture samples are cooled if immediate inoculation isn't possible. Blood and other fluids can be dressed in a Castaneda bottle, incubated with 5- 10 CO<sub>2</sub>. Other blood culture systems may be used for discovery of *Brucella*, but for optimal discovery mores are demanded. Akins, stringy clots and exudates should be invested onto SBA, CA, MAC, and, if available, BCYE, after being aseptically crushed.

When impurity is likely, a picky medium should be used, similar as Farrell's medium, or modified Thayer — Martin medium (16). All societies should be incubated for 21 days in 5- 10 CO<sub>2</sub> at 35- 37 °C; for mores, 7 days of incubation is sufficient. *Brucella* grows sluggishly, forming small, on-hemolytic, glistening, convex, bluish — white colonies on SBA. A plausible identification of *Brucella* can be made on the base of the Gram stain; non-hemolytic colonies that don't raise glucose or lactose are obligate aerobes, and are oxidase and urease positive. Urease product can fluently be detected on Christensen urea agar. The definitive identification of *Brucella* species is grounded on CO<sub>2</sub> demand, H<sub>2</sub>S product, perceptivity to fuchsin, thionin and thionin blue colorings, and cohesion with monospecific sera(). Clinical laboratories that aren't suitable to identify *Brucella* species definitively should try a plausible identification/ isolation with other coccobacilli, leaving the definitive identification to a reference laboratory [7].

Human pest is caused by pasties, and there are three clinical forms bubonic pest, pneumonic pest, generally secondary to bubonic pest, and a septicemic form. *Y. Pestis* is a Gram-negative, facultative anaerobe, and is a member of the Enter- obacteriaceae. In a smear, fat, single or short- chained, occasionally bipolar, bacilli can be seen. Indeed though the bipolar staining e.g. in a Wright — Giemsa stain, is typical of *Yersinia*, it isn't enough to identify the organism. Like other *Yersinia* species. *Pestis* doesn't reply, or reacts unreliably, in generally used biochemical tests. It's a finical organism that doesn't form spores and is non-motile.

Lymph knot aspirates, spleen or liver necropsies and blood and foam samples are invested on SBA and MAC and in brain — heart infusion broth. Bacteremia is characteristically intermittent, so multiple blood societies should be done to increase perceptivity. The optimal growth temperature of *Pestis* is between 25 °C and 30 °C(). thus, for rapid-fire recovery of the organism, the samples should be incubated at 28 °C. *Y. pestis* expresses a temperature- regulated antigen( F1) when incubated at 37 °C that can be used for identification( 20). Colonies

grow sluggishly on SBA and have the appearance of fried eggs when viewed under the stereomicroscope. After incubation for 48 h, the colonies are non-hemolytic, 1- 2 mm in periphery, argentine-white to slightly unheroic, and opaque( 20). *Y. pestis* grows as lactose-negative colonies on MAC. After 24- 48h in brain- heart infusion frothy. *pestis* gives characteristic growth of flocculent or crispy clumps at the sides and bottom of the tube, while the rest of the medium remains clear( 20). The clumps stay visible indeed in a cloudy, polluted broth culture [8-10].

## Conclusion

Although the cementing growth in brain- heart infusion broth is veritably suggestive. Pseudotuberculosis and *Streptococcus pneumoniae* may parade the same type of cementing growth can be discerned by urease product, being positive and negative, is detected in serum samples by an immunoassay. Molecular discovery styles include a 5' - nuclease PCR, for the discovery of the plasminogen activator gene in blood and or pharyngeal hearties, and a microchip PCR array. The assays have discovery thresholds of  $2.1 \times 10^5$  clones of the plat target and of 105 cells/ L, independently. The viral hemorrhagic fever pattern may be caused by several RNA contagions from the Filoviridae, Arenaviridae, Bunyaviridae, and Flaviviridae. These contagions are largely contagious by the aerosol route. Only BSL- 4 installations are equipped for the opinion of viral hemorrhagic complications. Culture, serology, Immunohistochemical ways and modification styles are used for opinion. Blood, urine and throat hearties or washings are used for contagion insulation; liver necropsies are used posthumous. Contagion insulation is generally successful only if samples are attained within the first many days of illness. For insulation, blood, cerebrospinal fluid, brain or other napkins should be collected, and cooled at 4 °C. Heparinized whole blood or homogenized clots are satisfactory for contagion insulation.

## Acknowledgement

None

## Conflict of Interest

None

## References

- Lange C, Dheda K, Chesov D, Mandalakas A M, Udwadia Z, et al. (2019) Management of drug-resistant tuberculosis. *Lancet* 394: 953-966.
- Zhao Y, Shaofa X, Lixia W, Daniel P C, Wang S, et al. (2012) National survey of drug-resistant tuberculosis in China. *N Engl J Med* 366: 2161-2170.
- Song W M, Fan L, Ma X, Liu J, Ning N T, et al. (2019) Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004-2018.
- Lin M, Zhong Y, Chen Z, Lin C, Pei H, et al. (2019) High incidence of drug-resistant Mycobacterium tuberculosis in Hainan Island, China. *Trop Med Int Health* 24: 1098-1103.
- Larson C L, Wicht W C (1964) Infection of mice with Mycobacterium tuberculosis, Strain H37ra. *Am Rev Respir Dis* 90: 742-748.
- Yuengling K A, Padayatchi N, Wolf A, Mathema B, Brown T, et al. (2018) Effect of antiretroviral therapy on treatment outcomes in a prospective study of extensively drug-resistant tuberculosis (XDR-TB) HIV coinfection treatment in KwaZulu-Natal, South Africa. *J Acquir Immune Defic Syndr* 79: 474-480.
- Serrano M J, Alcalá K, Martínez L, Díaz M, Marin M, et al. (2000) In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs. *Antimicrob Agents Chemother* 44: 2567-2568.
- Martin L J, Roper M H, Grandjean L, Gilman R H, Coronel J, et al. (2016) Rationing tests for drug-resistant tuberculosis who are we prepared to miss?. *BMC Med*

9. Nahid P, Mase S R, Migliori B G, Sotgiu G, Bothamley G H, et al. (2019) Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.
10. Wu X, Yang J, Tan G, Liu H, Liu Y, et al. (2019) Drug resistance characteristics of *Mycobacterium tuberculosis* isolates from patients with tuberculosis to 12 antituberculous drugs in China. *Front Cell Infect Microbiol*.